506508915 02/17/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6555691

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the ASSIGNEE'S ADDRESS previously recorded on Reel 055259 Frame 0142. Assignor(s) hereby confirms the ASSIGNMENT.

CONVEYING PARTY DATA

Name	Execution Date
BRIAN K. KASPAR	06/05/2020

RECEIVING PARTY DATA

Name:	NATIONWIDE CHILDREN'S HOSPITAL	
Street Address:	700 CHILDREN'S DRIVE	
City:	COLUMBUS	
State/Country:	ОНЮ	
Postal Code:	43205	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16406904

CORRESPONDENCE DATA

Fax Number: (312)474-0448

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3124746300

Email: docket@marshallip.com,lfrasher@marshallip.com

Correspondent Name: MARSHALL, GERSTEIN & BORUN LLP

Address Line 1: 233 SOUTH WACKER DRIVE
Address Line 2: SUITE 6300, WILLIS TOWER
Address Line 4: CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER:	33057/47099F
NAME OF SUBMITTER:	SHARON M. SINTICH
SIGNATURE:	/Sharon M. Sintich/
DATE SIGNED:	02/17/2021

Total Attachments: 7

source=47099F Assignment to NCH_Kaspar#page1.tif source=47099F Assignment to NCH_Kaspar#page2.tif source=47099F Assignment to NCH_Kaspar#page3.tif source=47099F Assignment to NCH_Kaspar#page4.tif

PATENT 506508915 REEL: 055318 FRAME: 0827

source=47099F Assignment to NCH_Kaspar#page5.tif source=47099F Assignment to NCH_Kaspar#page6.tif source=47099F Assignment to NCH_Kaspar#page7.tif

> PATENT REEL: 055318 FRAME: 0828

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby agreed, [insert inventors] ("Assignor") agrees to assign and hereby does assign to **Nationwide Children's Hospital**, 700 Children's Drive, Columbus, Ohio 43205, and its successors and assigns ("Assignee") all rights, title, and interests in and to the inventions that are disclosed in the application listed in Schedule A (the "Applications") including, but without limitation, all rights:

- i) in and to the Application and all other applications anywhere in the world that have been or may be filed on said inventions and/or naming Assignor as an inventor of said inventions,
- (ii) in and to any and all applications claiming priority benefit of the applications listed above, including all continuations, divisionals, and continuations-in-part,
 - (iii) in and to all patents issuing on any of the foregoing.

35

- (iv) in and to all reissues, reexaminations, supplemental examinations, inter partes reviews, oppositions, post-grant reviews, supplementary protection certificates, and/or extensions of any of the foregoing,
- (v) to bring suit, the right to claim and retain all damages and/or seek other remedies for the past, present, and future infringement and/or misappropriation of any of the foregoing, and
- (vi) of priority including, but without limitation, the right to claim priority benefit of or to the
 Application and all of the foregoing.

Assignor requests the Commissioner for Patents in the United States and similar authorities outside the United States to issue said patents to and in the name of Assignee or its designee. Assignor authorizes the attorneys of record in the application to insert in this assignment the filing date and application number of the Application when officially known. Assignor:

(a) declares: (1) The application was made or authorized to be made by me, (2) I believe myself, as a named inventor, to be the original inventor or an original joint inventor of a claimed invention in the applications listed in Schedule A, and I understand that any willful false statement made by me in this paragraph is punishable under 18 U.S.C. §1001 by fine or imprisonment of not more than five years, or both:

- b) warrants except in favor of Assignee: (1) Assignor is the owner of all its rights, title and interests herein assigned and has the right to make this unconditional and irrevocable assignment to Assignee without obtaining any approval or permission of a third party; and (2) there are no outstanding encumbrances, liens, prior assignments, licenses, or other obligations or restrictions on the rights, title and interests herein assigned; and
- (c) agrees to execute, upon the request of Assignee or its designee at no expense to Assignor, all applications or documents related to the inventions including, but without limitation, any oath, declaration, or affidavit relating thereto that Assignee may deem necessary or expedient, and to fully cooperate with Assignee and/or its designee to perform all affirmative acts requested to prepare, file, prosecute, maintain, defend, enforce, and vest in Assignee the rights, title, and interests assigned herein whereby said rights, title and interests will be held and enjoyed by Assignee or its designee to the full end of the term for which the intellectual property rights herein may be available as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made.

ASSIGNOR 13 L Karper with my hand this 05 day of June, 2020.
Brian K. Kaspar
State of <u>California</u>
State of California County of San Daga
On this
WITNESS my hand and seal the same day and year last above given. My commission expires: <u>ハッノ</u> ス, コウュウ
Michelle Fredericksen
MICHELLE FREDERICKSEN Notary Public Signature Notary Public - Celifornia Reg Change County

On behalf of Assignee,	Rhonda Comer	·	
-	Name	Charles Committee and Committe	
	Vice President, Legal Services		
	Title		
hereby confirms Assignee's acceptance.			
	Ä		
	Thomas Cenu	<u>July 23 2020</u>	
	Signature	Date /	

Schedule A For Recordal of Assignment

MG Matter No.	NCH Ref. No.	Country	Title	App. No.	Filed
28335/47099PCT	2012-022-02	PC	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	PCT/US2013/05 3065	7/31/2013
28335/47099US	2012-022-08	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	14/417,823	1/28/2015
28335/47099CON	2012-022-11	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	15/997,433	6/4/2018
28335/47099CON2	2012-022-30	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	16/502,944	7/3/2019
33057/47099A	2016-051-01	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	15/488,203	4/14/2017
33057/47099B	2016-051-02	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	15/863,429	1/5/2018
33057/47099C	2016-051-05	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	16/129,096	9/12/2018
33057/47099D	2016-051-06	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	16/247,380	1/14/2019
33057/47099E	2016-051-07	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	16/247,420	1/14/2019
33057/47099F	2016-051-10	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	16/406,904	5/8/2019
33057/47099G	2016-051-11	US	Intrathecal Delivery of Recombinant Adeno- Associated Virus 9	16/406,895	5/8/2019

5

PATENT REEL: 055318 FRAME: 0833